Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0851184 (thinning)
 11,252 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Twenty eight patients with various dermatological conditions were treated orally with the new aromatic derivate of retinoic acid, Ro 10-9359. The initial average dose was 48,3 mg/day and the maintenance dose was 26,6 mg/day. Duration of treatment ranged between 3 to 6 months. Evolution of erythema, infiltration and hyperkeratosis showed changes statistically significant (p < 0,05) and excellent to good results were obtained in 23 out of the 28 treated patients. On the basis of this study it is concluded that Ro 10-9359 is a promising drug for the treatment of several skin diseases, specially ichthyosis, Darier's disease, oral lichen planus, erythrokeratoderma variabilis and psoriasis. No serious side effects were reported; dryness of the lips, scaling of palms and soles, pruritus and thinning of the skin were the most common. In no case treatment was discontinued due to side effects. Laboratory controls did not show deviations from the normal values.
 ...
PMID:[Oral treatment of various dermatosis with the aromatic derivative of retinoic acid Ro 10-9359]. 39 25

The aromatic retinoic acid derivative Ro 10-9359 was administered orally to 25 severe psoriatic patients (14 with generalized plaques, 7 erythrodermic, 4 pustular). The initial dose was 25 mg/20 kg body weight daily for 4 weeks; afterwards the same posology was given every other day during several months (Max : 18 months). Excellent results were obtained in 16 patients (64 p. 100) particularly in severe erythrodermic and pustular psoriasis. However, under follow-up therapy relapses sometimes occurred leading to temporary resumption of initial posology. The most important side effects are cheilitis, palmoplantar scaling with thinning of the skin, hyperhidrosis and diffuse hair loss. A slight increase of transaminases and of alkaline phosphatases was found in a few patients. The Ro 10-9359 compound is a very useful new therapy of severe psoriasis.
 ...
PMID:[Oral treatment of severe psoriasis with a new aromatic retinoid (Ro 10-9359) (author's transl)]. 74 93

In a patient with systematized verrucous epidermal nevus, marked improvement was obtained with oral administration of a new aromatic retinoid (Ro 10-9359). Mild cheilitis and thinning of scalp hair were the only side effects obser Withved. continuous treatment the good result was maintained for 10 months. Further investigation is needed to determine, whether long-term oral administration of this new drug is feasible.
 ...
PMID:Systemic retinoid therapy of systematized verrucous epidermal nevus (with 1 colour plate). 90 29

Clinical, roentgenographic and biologic features of etretinate bone toxicity in a 13-year-old girl with pachyonychia congenita syndrome are reported. Etretinate is a synthetic derivative of vitamin A that infrequently induces bone and joint abnormalities in children. The following manifestations can be observed: cortical hyperostosis, pain, calcification of tendons, thinning of long bones, demineralization, premature closure of epiphyses, or abnormal remodelling. Onset of these anomalies is often delayed since etretinate has a long half-life. Mechanisms are unknown. We advocate use of the minimum effective dosage and regular monitoring of patients.
 ...
PMID:[Bone complications from chronic etretinate intoxication in children]. 225 41

Etretinate is recognized to have unwanted cutaneous effects such as dryness of the skin, pruritus and hair thinning. Photosensitivity has rarely been observed as an adverse reaction but we now describe a renal transplant recipient who developed lesions of cutaneous porphyria apparently as a result of etretinate prescribed to suppress cutaneous neoplasia.
 ...
PMID:Pseudoporphyria complicating etretinate therapy. 260 7

The effects of chronic hypervitaminosis A and long-term isotretinoin treatment on bone include cortical hyperostosis, ligament calcification and premature epiphyseal closure. Similar effects have now been reported in patients under maintenance treatment with etretinate in high doses. Etretinate, an oral, aromatic, synthetic vitamin A derivative, is widely used in Europe for disorders of keratinization. We report the cases of two patients--one with lamellar ichthyosis, the other with pachyonychia congenita--who developed such bone diseases during treatment with etretinate over 2 and 6 years respectively. The doses ranged from 0.5 to 1 mg/kg/day. Two years after starting treatment (total dose 25 g), the patient with lamellar ichthyosis complained of mechanical pain in the lumbar region and hips. Radiography showed calcification of the extraspinal tendons and ligaments and hyperostosis of the calcaneus bone at the insertion of the plantar ligament. After six years of etretinate treatment (total dose 50 g), the patient with pachyonychia congenita presented with scoliosis and limb length discrepancy. The musculoskeletal abnormalities resembled chronic hypervitaminosis A, with such osseous changes as demineralization, thinning and increased curvature of long bones with osteopenia, and premature closure of the epiphyses. Acroosteolysis was also present. Etretinate has been implicated in the formation of spinal hyperostoses and calcification of extraspinal ligaments in patients who had taken the drug for many years. The occurrence of premature epiphyseal closure in children certainly is a consequence of therapy with relatively high doses of etretinate for six years. But premature epiphyseal closure may also result from trauma to a fragile bone.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Rheumatologic effects of etretinate]. 266 Jul 11

Tigason (etretinate, RO-10-9359) is an oral aromatic retinoid acid which is effective in psoriasis and other dermatological syndromes. The present study reports the results of the use of this drug in 15 patients with a confirmed diagnosis of psoriatic arthritis, aged between 42 and 74 (average 60.2) years. Two patients dropped out after one month because they showed dryness of lips, chapping and intolerable itching, and another two due to intolerable pruritus and deterioration of their skin lesions. The 11 remaining patients, five males and six females, were treated with a daily dose of 50 mg etretinate, reduced to 25 mg after two weeks. Assessments which included grip strength, Ritchie joint index, pain, and dermatological assessment were performed at monthly intervals. Routine blood tests for toxic effects and erythrocyte sedimentation rate (ESR) were also performed, as well as CPR (C-protein reactive) as a test of disease activity. All patients showed an improvement in the psoriasis, joint swelling and pain. The elevated ESR observed in all patients studied also fell gradually during the course of etretinate treatment, as did as the intake of antiinflammatory agents. Elevated serum lipid levels (cholesterol and triglycerides) were found in three patients; further drug-specific side-effects such as dryness of lips and mouth, loss of hair, thinning of skin and scaling were frequently found in all patients, but they remained tolerable.
 ...
PMID:Tigason (etretinate) treatment in psoriatic arthritis. 339 51